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Summary A set of mouse nonoclonal antibodies against the c-myc oncogene product, a 62,000 dalton
nuclear binding protein involved in cell cycle control, has been constructed by immunisation with synthetic
peptide fragments. One such antibody, CT14, was radiolabelled with 1311 and administered to 20 patients
with different malignant diseases. Good tumour localisation was observed in 12 out of 14 patients with
primary bronchial carcinoma but not in patients with pulmonary metastases from primary tumours elsewhere.
Successfully localised tumours were all 3 cm or more in diameter. Monoclonal antibodies against oncogene
products may provide novel selective tools for the diagnosis and therapy of cancer.
Despite intensive clinical study the overall survival
for patients with lung cancer remains dismally
short. The advent of aggressive chemotherapy has
had only minimal impact on the survival of those
patients with metastatic disease (Souhami, 1984).
New approaches to provide selective tumour cell
destruction are therefore urgently needed. The
demonstration that human cancer cells express
unique segments of DNA, called oncogenes,
provides an exciting new avenue for clinical investi-
gation (Bishop, 1984; Cooper & Lane, 1984). Over
25 of these genes have been identified, molecularly
cloned and sequenced. Changes in the coding or
control regions of these genes have been implicated
in the development of several tumour types
including bronchial carcinoma (Krontiris, 1983; Der
& Cooper, 1983). New strategies for systemic
therapy may emerge by understanding more about
these genes and their products.
There is now good evidence that the proteins
coded for by oncogenes are involved in growth
control. At least one (c-sis) is related to a growth
factor (Waterfield et al., 1983). and another (c-erb-
B) to the internal component of the surface
receptor for a growth factor (Downward et al.,
1984). The c-myc gene product is particularly
intriguing with regard to human cancer. Several
studies have shown that this oncoprotein regulates
cell division and differentiation (Rabbitts et al.,
1985; Pfeifer-Ohlsson et al., 1984). The protein
appears to be associated with cell nuclei, a likely
site for such control. Both mRNA transcripts and
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the protein itself have unusually short half lives
of 20-30min, a prerequisite for their putative cell
cycle control function (Pauza & Evan, 1986).
Furthermore the level of c-myc mRNA increases as
an early event when cells are stimulated into
division (Kelly et al., 1983). The c-myc gene has
been found to be amplified in several lung cancer
cell lines (Little et al., 1983). Levels of c-myc RNA
have also been noted to be elevated in biopsy
samples from lung tumours of several histological
types.
In order to examine the relevance of the c-myc
oncoprotein in clinical samples we have constructed
a set of monoclonal antibodies (MCAs) by
immunisation with synthetic peptides (Evan et al.,
1985). The DNA sequence of the c-myc gene was
used to predict the amino acid structure of the
oncoprotein. Two peptides of 18 and 32 amino
acids in length were synthesised. The regions chosen
for synthesis and immunisation were predicted to
be exposed within the intact molecule by assessing
the relative hydrophobicity of different parts of the
sequence. Six MCAs were produced that reacted to
the 62,000 dalton protein identifiable with the c-
myc product (p62c-mYc) (Evan et al., 1985).
A possible tool in the detection and localisation
of tumours is a suitably labelled tumour specific
antibody. Several studies have shown that both
polyclonal and monoclonal antibodies against cell
surface antigens can effectively localise tumours
(Mach et al., 1981; Smedley et al., 1983). However,
the images obtained could be improved by the use
of more tumour specific reagents. After labelling
with radioiodine, one anti c-myc gene product
antibody was found to localise human tumour
xenografts in immunosuppressed mice. This
antibody was therefore evaluated for its ability to
localise bronchial carcinoma in patients.
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Materials and methods
Monoclonal antibody production
Peptide synthesis, the immunisation protocol and
screening procedures for deriving CT14 MCA (an
IgGiK) are described elsewhere (Evan et al., 1985).
Hybridoma cells were grown in the ascites fluid of
female BALB/c mice. The antibody was purified by
octanoic acid precipitation followed by ammonium
sulphate concentration. Purified antibody was
stored in PBS with 0.001% sodium azide, aliquoted
and stored at -20°C. A non-specific monoclonal
mouse immunoglobulin IgGlIK was used as a
control prepared in the same manner.
Iodination
Five mg of purified antibody in a total volume of
PBS of 50,u1 was added to an LP3 tube. Ten pl of
chloramine T (BDH) at a concentration of
I mgml-1 in fresh distilled water was added.
Immediately 5mCi of 1311 iodide (200mCiml -1,
Amersham International) was added in a fume
cupboard. The tube was stoppered and incubated at
room temperature for 2min. After this time, 50tl
of saturated tyrosine was added to terminate the
reaction. A biogel PlO column was used to separate
iodinated antibody from free iodine. lodinated
antibody was pooled and sterilized using a millipore
22,um filter. This preparation was shown to localise
xenografts of Colo-320 human apudoma cells
growing in nude mice (Chan et al., submitted).
Such tumours are known to express considerably
elevated levels of p62c-myc.
ELISA assay
Affinity of the labelled and unlabelled CT14 MCA
to the synthetic peptide used for their production
was compared in an ELISA assay. Fivepmoles of
the peptide in 100kd of 0.1 M sodium bicarbonate
buffer (pH 9.6) was added to each well of an
'Immulon 2' microtitre plate (Dynatech, Ltd.) for
overnight incubation at room temperature.
Unabsorbed peptides were removed by washing
with TBS (25mM Tris HCl 144mM NaCl pH 8.1).
This was followed by two 30min incubations at
room temperature with serial dilution of CT14
MCA in TBS containing 10% foetal calf serum;
and then 100pl per well of 1: 150 dilution of rabbit
anti-mouse Ig-horseradish peroxidase conjugate
(Dako Ltd.), with washing in TBS between the
steps. Quantitation of the bound CT14 MCA was
provided by colour change on addition of the
enzyme substrate (1 mM ABTS (Boehringer
Mannheim Ltd.) in 0.1 M sodium citrate pH 5.0
and 1:1000 of 30% H202) and incubated in the
dark for 30min. Optical density of each well was
measured by spectrophometry at 406mM using an
ELISA plate reader.
Clinical studies
Informed consent was obtained from all patients.
Potassium iodide tablets (120mg daily) were given
orally for 2 days, from the day of antibody
injection, to block thyroid uptake of radioiodine.
One mg of CT14 labelled with 1 mCi 1311 in l0ml
normal saline was injected i.v. Serum samples in 6
patients were collected at 0, 1, 2, 4, 8, 24, 48 h after
the administration of CT14. The samples were
counted for 1311 activity both before and after TCA
precipitation to determine protein bound and free
131 . Scanning using a gamma camera (IGE480)
was performed at 24h and 48h after antibody
injection. Thirty minutes prior to each scan patients
were given 0.5mCi of a standard technetium
labelled human serum albumin (HSA) i.v. to
delineate the blood pool.
Images of the distribution of HSA and CT14
were recorded on a Nodecrest computer which
simultaneously recorded the energy peaks of 99MTc
and 13'I respectively. The ratio of 1311 and 99MTc
counts over the ventricular chambers, which is
predominantly blood pool in nature, provides the
standard for correction of circulatory antibody. The
computer subtracts the 1311 image, pixel by pixel
using this standard and produces an image which
represents, by means of colour variation, areas of
high concentration of bound 1311 antibody. Twenty
patients with histologically proven cancer were
studied: 14 with primary bronchial carcinoma; 4
with pulmonary metastases from tumours at other
sites and 2 with localised primary tumours at sites
outside the thorax.
Results
Results of the ELISA assay (Figure 1) showed that
the 131-iodine labelled CT14 MCA has retained its
affinity to the synthetic peptide. Figure 2 shows the
serum levels of 1311, measured as radioactivity per
ml of blood detected by a gamma counter.
Trichloroacetic acid precipitation showed that 90%
of the 1311 remained protein bound. The mean half
life of CT14-1311 was 20h and the slope of decay
similar in all patients studied.
Good tumour localisation was seen in 12 out of
14 patients with primary bronchial carcinoma
(Table I). Examples of the scans ar'd radiological
investigations are shown in Figures 3-7. All 12
patients had primary tumours of greater than 3 cm
diameter. The 2 patients who gave no evidence of
tumour localisation had smaller tumours - less than
2cm diameter. Several patients giving good primaryDETECTION OF C-MYC ONCOGENE PRODUCT IN LUNG CANCER 763
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Figure 1 ELISA assay of CT14 anti p62'-'Y" activity
before (0) and after (A) iodination.
Table I Patients with primary bronchial
carcinoma.
CTJ4-131I
No. Age Sex Histology scan ofchest
1 64 M SCLC +
2 55 M SCLC +
3 61 M SCLC +
4 64 F SCLC +
5 60 M SCLC +
6 72 M SCLC +
7 65 F SCLC +
8 48 M Squamous +
9 73 M Squamous
10 72 M Squamous +
11 69 M Adeno +
12 64 F Adeno
13 48 M Adeno +
14 60 M LCLC +
SCLC=Small cell lung cancer and LCLC=Anaplastic
large cell lung cancer.
Table II Patients with preliminary metastases.
CTJ4-'31I
No. Age Sex Primary tumours scan ofchest
15 38 M Malignant melanoma
16 32 F Breast cancer
17 62 F Colonic cancer
18 80 M Colonic cancer
19 49 M Glioma
20 70 M Rectal cancer
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Figure 2 Serum levels of 1311-CT14 after i.v. injection
into 6 patients.
tumour images had documented evidence of
metastatic disease in liver, bone and brain.
However, there was no evidence of increased
uptake at the sites of metastases.
None of the 6 patients with pulmonary
metastases showed tumour localisation. These
patients all had multiple small metastases each less
than 2cm diameter (Table II). A patient with a
primary glioma and another with locally recurrent
rectal carcinoma gave no evidence of increased
uptake within the thorax.
A control study was performed using I mg of
non-specific mouse IgG labelled with 1 mCi 1311.
Figure 4d shows the image obtained in a control
scan in patient 5 whose primary lung tumour
clearly demonstrated increased uptake of CT14-
131I. This scan was performed 7 days after the
administration of labelled MCA. No evidence of
tumour uptake was observed.
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Figure 3 Patient 5 - Large left upper lobe tumour. (a) Chest X-ray; (b) subtraction scan; (c) composite of
scanning data showing 1311 counts, 99MTc counts and subtraction, 48h after injection of MCA.DETECTION OF C-MYC ONCOGENE PRODUCT IN LUNG CANCER
Figure 4 Patient 5 scanned with control IgG showing no tumour uptake either on primary scan or after
subtraction 48h after injection.
Discussion
We believe this to be the first report of tumour
localisation by a monoclonal antibody against an
oncogene product. In the majority of patients with
primary bronchial carcinoma good tumour
localisation corresponding to the chest X-ray and
CT scan images was seen. There is good evidence
from immunoprecipitation and immunoblotting
data with fresh tumour lysates that CT14 binds
specifically to p62c-mYc (Sikora et al., 1986).
Furthermore, high levels of c-myc RNA have been
reported in primary bronchial carcinomas
indicating that the c-myc oncoprotein is likely to be
abundant (Slamon et al., 1984).
The c-myc protein is normally associated with
cell nuclei. From this site that it is thought to exert
a controlling function on cell division and differen-
tiation. In large primary tumours, cell death will
release nuclear contents into the surrounding extra-
cellular space. It is presumably here that p62c-mYc is
being detected by radiolabelled MCA. Patients with
small primary or metastatic tumours showed no
tumour localisation. This may well be due to lack
of sufficient tumour necrosis to significantly
increase the extracellular p62c-mYc level to detectable
levels.
Because of their low sensitivity, it is unlikely that
such scans will be useful in detecting disease not
visualised by conventional radiological means.
However, the level of p62c-mYc in and around a
tumour may provide a new biological pointer to
tumour behaviour and response to therapy. The
prompt disappearance of p62c-myc image shortly
after chemotherapy may be the earliest indication
of tumour response. Furthermore, the shedding of
this oncoprotein by tumour cells into the blood
stream could well provide a new marker of tumour
load. The development of a suitable assay to test
this hypothesis is currently in progress.
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Figure 5 Patient 7. (a) Chest X-ray showing left hilar carcinoma with disease in ipsilateral pleura; (b) CT
scan from same patient; (c) subtraction scan: (d) composite as Figure 3 - 48 h after MCA.DETECTION OF C-MYC ONCOGENE PRODUCT IN LUNG CANCER 767
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Figure 6 Patient 11 showing tumour in right upper lobe. X-ray and scans as for Patient 5 (Figure 3).t
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Figure 7 Patient 2. (a) Chest X-ray showing tumour in right mid and lower zones; (b) CT scan; (c)
unsubtracted MCA image at 48 h.
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